Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

Shares of Hims & Hers slid after Amazon.com said it would offer cheap treatments for concerns like hair loss, skin care and ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

A recent study that found there has been a massive increase in type 2 diabetes cases worldwide since 1990 is an indication ...

Results from the SURMOUNT-1 trial show that weekly injections of tirzepatide could stop the progression from pre-diabetes to ...

Has something changed regarding Eli Lilly or Regeneron's thesis, or is the recent dip an excellent opportunity to invest in ...

The weight loss drugs Ozempic and Wegovy may be beneficial for people struggling with alcohol addiction, a study published ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

and tirzepatide (Mounjaro and Zepbound; Eli Lilly), a dual GLP-1/glucose-dependent insulinotropic peptide (GIP) agonist. That ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

Medications such as semaglutide (branded as Ozempic and Wegovy) and tirzepatide (branded as Mounjaro and Zepbound) work by ...